Login to Your Account



Dolutegravir Combo Beats Atripla in Head-to-Head Trial

By Catherine Shaffer
Staff Writer

Thursday, July 12, 2012
Shionogi-ViiV Healthcare LLC's HIV drug dolutegravir beat Gilead Sciences Inc.'s Atripla in a Phase III trial in treatment-naive adults with HIV-1 infection. Initial results showed that 88 percent of patients receiving dolutegravir with Kivexa/Epzicom (abacavir/lamivudine) were virologically suppressed, compared to 81 percent on Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription